St Phi Therapeutics is an innovative company specializing in immune cell therapies, particularly focused on treating solid tumors and developing allogeneic cell technologies. The company boasts several proprietary platform technologies, including CNK-T cell technology, which is designed to overcome the immune suppression barriers present in solid tumors, enhancing the activation and destruction of cancer cells. Additionally, the VAC-T cell technology is notable for its ability to internalize and present tumor or viral antigens, effectively inducing and recruiting specific immune cells to mount a multifaceted attack against tumors.

Another significant technology is the U-T allogeneic cell technology, which ensures the safety and timeliness of allogeneic cell therapies, facilitating large-scale production and standardized treatment protocols. These advanced technologies position St Phi Therapeutics at the forefront of cell therapy innovation, aiming to provide effective solutions for challenging cancer treatments and improve patient outcomes.

China

The mission of the company is to develop innovative diagnostic reagents, cellular therapeutics technologies and engineered cell products to help

St Phi Therapeutics

Company Details